Pittsburgh Biopharmaceutical Company Receives $3.3m For Alzheimer’s Trial

Larry Richert and John Shumway
July 11, 2019 - 11:58 am
Grandmother with tender caregiver

iStock / Getty Images Plus

PITTSBURGH (Newsradio 1020 KDKA) - The National Institute of Aging granted $3.3 Million to Cognitive Therapeutics Inc. this week.  

“This particular grant will help us with another study of the electrical activity of the brain in Alzheimer’s patients,” said Ken Moch, Cognitive Therapeutics CEO, during an interview with KDKA Radio on Thursday.

There is a protein that we make in our body normally and it builds up as we age. That build up affects the electrical communication.

“We have a drug that we believe will knock that toxin off its particular toxic site. If that works, we should be able to restore the electrical communication, the communication between our brains” Moch explains.

This is the 8th grant the company has received from the National Institute of Aging.

You can learn more about the drug and Therapeutic Cognition in the full interview below.

___
Follow KDKA Radio: Facebook | Twitter | Instagram
Listen to KDKA Radio on the Radio.com App - Download Now